Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiation followed by PCA (Paclitaxel, Carboplatin, Bevacizumab) in Squamous NSCLC
NCT00334763Phase 2Terminated
- Sponsor
- Northwestern University
- Start
- May 2006
- Primary completion
- May 2007
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in non-small cell lung cancer (NSCLC), sponsored by Northwestern University. Primary endpoint: Reduction in toxicity measured by pulmonary hemorrhage rate. Started May 2006; status: terminated.
02
Drugs
bevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00334763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00334763.